(2R,3R,4S,5R)-2-{6-amino-2-[2-(4-chlorophenyl)ethoxy]-9H-purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3R,4S,5R)-2-{6-amino-2-[2-(4-chlorophenyl)ethoxy]-9H-purin-9-yl}-5-(hydroxymethyl)oxolane-3,4-diol
• 英文别名: 2-[6-amino-2-[2-(4-chlorophenyl)ethoxy]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₈H₂₀ClN₅O₅
• 分子量: 421.8
• InChiKey: WUCQGGOGHZRELS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  149
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• TARGETING PATHOGENIC B CELLS IN AUTOIMMUNITY
  申请人：Research Foundation for the STATE UNIVERSITY OF NEW YORK

  公开号：US20210311050A1

  公开（公告）日：2021-10-07

  The present disclosure is directed to methods of treating a disease associated with pathogenic B cells comprising administering to a subject in need thereof an effective amount of an Adora2A (adenosine A2A receptor) agonist. The method more specifically comprises: (a) obtaining a biological sample from a subject, wherein the sample comprises B cells; (b) detecting in the sample the presence of pathogenic B cells; (c) administering to the subject a pharmaceutically effective dose of an Adora2A receptor agonist (A2aR agonist) if pathogenic B cells are detected in step (b). The method may further comprise administering to the subject subsequent doses of a pharmaceutically effective dose of the A2aR agonist until pathogenic B cells are no longer detected.